WallStSmart

Merck & Company Inc (MRK)vsNexgel Inc (NXGL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 583726% more annual revenue ($65.77B vs $11.27M). MRK leads profitability with a 13.6% profit margin vs -28.5%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

NXGL

Avoid

28

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 6.7Quality: 4.5
Piotroski: 5/9Altman Z: -1.93
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued
NXGLUndervalued (+48.1%)

Margin of Safety

+48.1%

Fair Value

$2.70

Current Price

$0.56

$2.14 discount

UndervaluedFair: $2.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

NXGL1 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

NXGL4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.16M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.053/10

Elevated debt levels

Return on EquityProfitability
-80.5%2/10

ROE of -80.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : NXGL

The strongest argument for NXGL centers on Price/Book.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : NXGL

The primary concerns for NXGL are EPS Growth, Market Cap, Debt/Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while NXGL is a turnaround play — different risk/reward profiles.

NXGL carries more volatility with a beta of 0.74 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 28/100). NXGL offers better value entry with a 48.1% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Nexgel Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

NEXGEL, Inc. manufactures aqueous, electron beam crosslinked, high water content hydrogels and polymeric gels. The company is headquartered in Langhorne, Pennsylvania.

Want to dig deeper into these stocks?